Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

ubjects identified as responders to Amigal, treatment resulted in increased levels of the target enzyme (a-Gal A), as measured in white blood cells and in the kidney, and reduced levels of the target substrate (GL-3), as measured in renal interstitial capillary cells from kidney biopsies and in urine.

About Fabry Disease

Fabry disease is a lysosomal storage disorder caused by inherited genetic mutations in the GLA gene, which result in deficient activity of the enzyme alpha-galactosidase A (a-Gal A). Deficient a-Gal A activity leads to lysosomal accumulation of globotriaosylceramide (GL-3), which is believed to cause the various symptoms of Fabry disease, including pain, kidney failure and increased risk of heart attack and stroke. Amigal is designed to selectively bind to and stabilize a-Gal A, which facilitates proper trafficking of the enzyme to the lysosomes, where it is needed to break down GL-3.

Fabry disease is estimated to affect approximately 5,000 to 10,000 people in the developed world, but recent evidence suggests that the disease may be significantly under-diagnosed. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan designation for Amigal in the United States, and the European Commission has designated Amigal as an orphan medicinal product in the European Union.

Shire HGT Collaboration

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. Under the terms of the collaboration Shire will pay development and sales milestones up to a maximum of $390 million, and will also pay tiered, double digit royalties on net sales of the products. Shire also shares world-wide developmen
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Pepperl+Fuchs, a world ... MACTek Corporation, a leading provider of HART protocol ... to further extend its integrated solutions offerings and ... "We are pleased to add the ... said Jim Bolin , Pepperl+Fuchs, executive vice ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
(Date:8/31/2015)... , August 31, 2015 ... that the global cardiovascular monitoring and diagnostic devices ... is predicted to reach a value of approximately ... of 9.7% between 2013 and 2019. The title ... Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5
... JERUSALEM , June 2, ... oral drug delivery systems, announced,today that its subsidiary Oramed Ltd. ... ("Laser Detect"), an Israeli company listed on,the Tel Aviv Stock ... Entera Bio Ltd. ("Entera"). Under the terms of the agreement, ...
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) announced today that it ... June 10, 2010 at The Grand Hyatt Hotel in New York, ... will discuss the Company,s business strategy and historical financial performance at 11:30 ... , Attendance at ...
Cached Medicine Technology:Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 3Questcor to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:9/1/2015)... ... 2015 , ... PetPace, the provider of an innovative IoT ... today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Management Software packages in the US. Practice Management Software helps veterinarians manage every ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and government entities, announced today that it has hired Scott Sanderson, an experienced ... In this capacity, Sanderson will be responsible for establishing and managing new client ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Royal River ... new study that followed men and women for 19 years and found that, among ... did not take multivitamins. , The report is part of the September 2015 issue ...
(Date:9/1/2015)... ... September 01, 2015 , ... WorkCare, Inc., ... joined its medical management team as an Associate Medical Director. , WorkCare ... types in the U.S. and abroad. , Dr. Nelson has a diverse ...
(Date:9/1/2015)... ... , ... Two of Washington D.C.’s most respected chefs are using their global ... Recently named “the next big thing” in the culinary world by Elle Spain, award-winning ... behind food and reclaiming culinary traditions on the brink of extinction. According to Amy ...
Breaking Medicine News(10 mins):Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4
... Ill., and Rockville, Md., SAN JOSE, Calif., ... major fundraising events for the Coalition for Pulmonary,Fibrosis ... benefiting the,CPF collectively raised more than a half ... families fighting pulmonary fibrosis (PF) and,directly funds research. ...
... of Undergraduate and Graduate Programs, Now Offered at ... Board of Trustees, in,conjunction with President James J. Gozzo, ... its name to become Albany College,of Pharmacy and Health ... Board of Education, has been chosen to better reflect ...
... efficiently, study says , , THURSDAY, Oct. 16 (HealthDay News) ... the body, while being physically fit decreases it, according to ... 452 healthy men who had levels of different groups of ... cell count is a marker of inflammatory activity and is ...
... divorce, or even the loss of jobs or financial security, the mental ... inaccurate Stages Theory of Grief. At long last, Grief Recovery pioneers, Russell ... grief really is what it definitely isn,t. , ... Sherman Oaks, CA ...
... China, Oct. 16 /Xinhua-PRNewswire/ -- WuXi PharmaTech,(Cayman) ... pharmaceutical, biotechnology and,medical device research and development ... United States, today announced it has reached ... & Development, Division of,Janssen Pharmaceutica, N.V. (J&JPRD) ...
... 15 Young Innovations, Inc.,(Nasdaq: YDNT ) today ... with a live and on-demand web cast conference call ... live audio broadcast of the,call will be available through ... broadcast will also be available through the,Company,s website, ...
Cached Medicine News:Health News:CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 2Health News:CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 3Health News:Albany College of Pharmacy and Health Sciences - New Name, Same Commitment to the Advancement of Health Care 2Health News:Fatness Boosts Inflammation in Body 2Health News:Stages Of Grief Refuted As Inaccurate and Dangerous By Grief Recovery Institute Founders In Skeptic Magazine Article 2Health News:Stages Of Grief Refuted As Inaccurate and Dangerous By Grief Recovery Institute Founders In Skeptic Magazine Article 3Health News:Stages Of Grief Refuted As Inaccurate and Dangerous By Grief Recovery Institute Founders In Skeptic Magazine Article 4Health News:WuXi PharmaTech Expands Collaboration for Fully Integrated Services 2Health News:Young Innovations, Inc. Provides Third Quarter Conference Call Details 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: